Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02589041
Other study ID # IOGPGC10
Secondary ID
Status Completed
Phase N/A
First received October 22, 2015
Last updated August 11, 2017
Start date November 2015
Est. completion date April 2017

Study information

Verified date August 2017
Source ASST Gaetano Pini-CTO
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This prospective, double-blinded study evaluates intraneural ropivacaine 1% Minimal Effective Volume (MEV90) for ultrasound-guided (US) popliteal sciatic nerve block, with Up-and-down methodology.

To evaluate any neurological complications, an electrophysiological assessment will also be performed preoperatively and at 5 weeks after surgery.


Description:

At least 45 patients undergoing hallux valgus repair will be enrolled. A baseline bilateral sciatic nerve electrophysiological study will be performed preoperatively.

Patients will be placed in prone position and a high-frequency (8-12 MHz) linear array transducer (Snerve, Sonosite, USA) will be used to identify the sciatic nerve in a transverse cross-sectional view at the apex of the popliteal fossa. As the best view of the sciatic nerve with its paraneural and neural sheath, just proximal to the point of bifurcation, will be obtained, the nerve dimension (medial-lateral and cranio-caudal diameters) will be determined and registered.

An 80 mm 22-gauge needle (Sonoplex, Pajunk, Germany) will be inserted using the US-guided in-plane technique under the epineurium. The positioning will be evaluated injecting 1 ml of sodium-chloride 0.9% solution and observing the nerve swelling, if correct the local anaesthetic (LA) solution will be injected.

The first patient will receive 15 ml of ropivacaine 1% (150 mg). Following patients will receive LA volume based on Up-and-down methodology.

Clinical follow-up will be performed at 12, 24, 48 hours, 1 and 5 weeks and 6 months after surgery.

At 5 weeks electrophysiological study will also be performed in all patients and repeated at 6 months in case of positive findings.


Recruitment information / eligibility

Status Completed
Enrollment 45
Est. completion date April 2017
Est. primary completion date October 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age above 18 years old

- ASA I-III

- Signed informed consensus

Exclusion Criteria:

- ASA IV

- Unstable neurological disease

- DM type I-II

- Allergy to ropivacaine-mepivacaine

- Opioid chronic treatment

- Consensus refusal or not valid

- Rheumatoid arthritis

- Baseline electrophysiological study positive finding

- Postoperative intensive care required

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
intraneural sciatic nerve injection
A popliteal intraneural sciatic nerve block will be performed under ultrasound guidance. Minimal effective volume will be evaluated performing a randomization based on the Up-and-down methodology. A baseline and postoperative electrophysiological study will assess the presence of any neurological complication.
Drug:
Ropivacaine 1%


Locations

Country Name City State
Italy Istituto Ortopedico G. Pini Milan Milano

Sponsors (1)

Lead Sponsor Collaborator
ASST Gaetano Pini-CTO

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of the Intraneural Ropivacaine Minimal Effective Volume in 90% of patients (MEV90) 6 months
Secondary electrophysiological assessment of neurological deficit Electromyography of sciatic nerve bilaterally. Evaluation of velocity (m/Sec), amplitude (mV) and latency (mSec) of both peroneal and tibial components 5 weeks